System for monitoring safety and efficacy of mRNA nanoparticle platforms

Background

The widespread administration of mRNA vaccines has revolutionized modern medicine, offering unprecedented capabilities in preventing infectious diseases and advancing cancer therapies. To function effectively, these therapeutics rely on sophisticated delivery vehicles, such as lipid nanoparticles, to protect fragile genetic material and facilitate cellular entry. As the application of these nanoparticle platforms expands into new areas, including biopesticides, there is a critical need to rigorously evaluate their systemic safety. Understanding the comprehensive biological impact of these delivery systems is essential to ensure they do not trigger unintended immune responses in patients.

Despite the success of nanoparticle-based vaccines, current approaches to evaluating their safety remain limited. Standard toxicity studies predominantly rely on basic physiological and histological endpoints rather than high-resolution molecular techniques. Consequently, a significant knowledge gap exists regarding how these formulations alter gene expression in major organs—such as the heart, liver, and kidneys—beyond the initial injection site. Furthermore, conventional preclinical models typically utilize highly inbred laboratory animals, failing to accurately reflect human genetic diversity. This reliance on superficial safety markers and homogenous models prevents researchers from fully understanding potential inflammatory signaling and rare adverse events associated with existing delivery platforms.

Technology

This transcriptomic profiling solution utilizes advanced RNA sequencing (RNA-seq) to evaluate the molecular impact of mRNA vaccine delivery systems across major organs, including the liver, heart, kidney, adrenal glands, and lungs. Following intramuscular administration, the platform compares the gene expression changes induced by standard lipid nanoparticles (LNPs) against novel branched amphiphilic peptide capsules (BAPCs). To accurately model human genetic diversity, the methodology employs wild-derived murine models rather than conventional inbred laboratory strains. The system tracks dynamic biological responses, specifically monitoring genes associated with inflammatory pathways, sex-specific reactions, and potential off-target effects over multiple post-vaccination timeframes.

What sets this profiling methodology apart is its fundamental shift from traditional physiological and histological safety assessments to comprehensive transcriptomic analysis. By addressing a critical gap in understanding how mRNA formulations affect organs beyond the injection site, it offers high-resolution insights into vaccine safety. The strategic use of wild-derived mice significantly enhances the translatability of the data to human populations. Ultimately, this comparative approach uniquely de-risks existing LNP platforms while validating emerging BAPC technologies, providing regulatory agencies and pharmaceutical developers with critical molecular evidence to assess off-target effects and improve future nanoparticle-based therapeutics.

Benefits

• Provides comprehensive molecular insights into vaccine safety by using RNA sequencing to detect off-target effects and inflammatory signaling often missed by traditional physiological or histological markers.
• De-risks current and future nanoparticle delivery platforms, such as lipid nanoparticles (LNPs) and branched amphiphilic peptide capsules (BAPCs), by identifying potential adverse effects in major organs.
• Enhances the translatability of preclinical data to human populations by utilizing wild-derived murine models that better reflect human genetic diversity compared to standard inbred lab strains.
• Assists regulatory agencies in accurately evaluating the safety, efficacy, and unintended biological effects of novel nanoparticle delivery systems.
• Supports the development of safer, optimized delivery mechanisms for a broad range of commercial applications, including mRNA vaccines, cancer therapeutics, and RNA-based biopesticides.

Applications

• Nanoparticle delivery platform de-risking
• mRNA vaccine safety screening
• Cancer therapy delivery assessment
• Biopesticide delivery system evaluation
• Regulatory safety data generation

Additional info

This technology is a comparative transcriptomic profiling method using RNA sequencing to analyze gene expression changes in major organs of wild-derived mice. Following intramuscular administration of mRNA, it evaluates molecular and inflammatory responses in the liver, heart, kidney, adrenal glands, and lungs. By comparing lipid nanoparticles to branched amphiphilic peptide capsules, this approach identifies sex-specific gene expression and off-target effects to assess nanoparticle safety.